Literature DB >> 11094119

Menstrual-related changes in motoric function in women with Parkinson's disease.

K Kompoliti1, C L Comella, J A Jaglin, S Leurgans, R Raman, C G Goetz.   

Abstract

Questionnaire studies have found that parkinsonism worsens in women during the premenstrual period, when estrogen and progesterone levels are presumably at their nadir. To assess this patient-based observation and correlate motor signs with hormonal levels, the authors prospectively studied 10 menstruating women with PD in their "off" state, on 5 successive weeks. Although PD severity fluctuated during the study period, there was no significant correlation between the objective or subjective measures of parkinsonism and estrogen and progesterone levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11094119     DOI: 10.1212/wnl.55.10.1572

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 2.  Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?

Authors:  Rachel Saunders-Pullman
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 3.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

4.  Perimenstrual Fluctuations in Two Siblings With Early-Onset Parkinson's Disease.

Authors:  Fabienne S Sprenger; Klaus Seppi; Elisabeth Wolf; Werner Poewe
Journal:  Mov Disord Clin Pract       Date:  2014-05-19

5.  Allopregnanolone increase in striatal N-methyl-D-aspartic acid evoked [3H]dopamine release is estrogen and progesterone dependent.

Authors:  Ricardo J Cabrera; Claudia Bregonzio; Myriam Laconi; Alejandra Mampel
Journal:  Cell Mol Neurobiol       Date:  2002-08       Impact factor: 5.046

6.  Hormone replacement therapy and risk for neurodegenerative diseases.

Authors:  Richelin V Dye; Karen J Miller; Elyse J Singer; Andrew J Levine
Journal:  Int J Alzheimers Dis       Date:  2012-04-04

7.  Male/Female differences in neuroprotection and neuromodulation of brain dopamine.

Authors:  Mélanie Bourque; Dean E Dluzen; Thérèse Di Paolo
Journal:  Front Endocrinol (Lausanne)       Date:  2011-09-30       Impact factor: 5.555

8.  Estrogen agonist genistein differentially influences the cognitive and motor disorders in an ovariectomized animal model of Parkinsonism.

Authors:  Elaheh Arbabi; Gholamali Hamidi; Sayyed Alireza Talaei; Mahmoud Salami
Journal:  Iran J Basic Med Sci       Date:  2016-12       Impact factor: 2.699

9.  Sexual dimorphism in Parkinson's disease: differences in clinical manifestations, quality of life and psychosocial functioning between males and females.

Authors:  Farzaneh Farhadi; Kia Vosoughi; Gholam Ali Shahidi; Ahmad Delbari; Johan Lökk; Seyed-Mohammad Fereshtehnejad
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-01       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.